About 200 reports

  • AJCC STAGING OF PROSTATE CANCER
  • 2 Prostate Cancer: Executive Summary

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026 Summary Prostate cancer (PCa) is the second most common cancer in men worldwide, after skin cancer. It accounts for 12% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While...

  • Cancer
  • Prostate Cancer
  • Therapy
  • Japan
  • PROVENGE group
  • 3.5 EPIDEMIOLOGICAL FORECAST FOR PANCREATIC CANCER (2016-2026)
  • MM, Diagnosed Incident Cases of Pancreatic Cancer by Cancer Stages at Diagnosis, Both Sexes, Ages ≥15

Pancreatic Cancer: Epidemiology Forecast to 2026 Summary Pancreatic cancer is one of the most fatal cancers around the world, with the highest incidence and mortality rates found in developed countries (Michaud, 2004).Pancreatic cancer occurs when cells in the pancreas develop mutations in their...

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • Japan
  • Forecast
  • MM, Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Site of Metastasis,
  • 2.4 ROCHE WILL CONTINUE TO MONOPOLIZE THE HER2-POSITIVE BREAST CANCER MARKET,

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. Today, HER2-positive breast cancer patients are living longer with their disease, thanks to established...

  • Cancer
  • Japan
  • World
  • Pfizer Inc.
  • Roche Group
  • TREATMENT DURATION IN COLORECTAL CANCER
  • KEY HISTORICAL AND PROJECTED LAUNCH DATES FOR COLORECTAL CANCER

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased...

  • Cancer
  • Japan
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • EFFICACY OF AVASTIN IN FIRST LINE METASTATIC BREAST CANCER
  • SAFETY OF AVASTIN IN FIRST-LINE METASTATIC BREAST CANCER

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer...

  • Cancer
  • China
  • Japan
  • Novartis AG
  • Pfizer Inc.
  • MM, Sources of CRC Cancer Stage at Diagnosis
  • MM, Diagnosed Incident Cases of CRC by Cancer Stage at Diagnosis (N), Ages ≥18

EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2025 Summary Colorectal cancer (CRC) is a cancer that starts in the colon or the rectum (ACS, 2016). CRC is one of the most common types of cancers diagnosed; it is the third most common cancer among men and the second most common in women, worldwide (Ferlay...

  • Cancer
  • Japan
  • World
  • Forecast
  • Cancer Epidemiology Group
  • MM, Sources of Bladder Cancer Incidence Data
  • 2.5 EPIDEMIOLOGICAL FORECAST FOR BLADDER CANCER (2015-2025)

EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2025 Summary Bladder cancer is a commonly diagnosed cancer and causes significant numbers of cancer deaths worldwide (Parkin, 2008; Ploeg et al., 2009). The major risk factors for bladder cancer are exposure to smoking and occupational risk factors such as exposure...

  • Bladder Cancer
  • Cancer
  • Pathology
  • Japan
  • Forecast
  • 2.5 EPIDEMIOLOGICAL FORECAST FOR OVARIAN CANCER (2015-2025)
  • 2.5.3 Age-Standardized Diagnosed Incidence of Ovarian Cancer

EpiCast Report: Ovarian Cancer - Epidemiology Forecast to 2025 Summary Ovarian cancer (International Classification of Diseases, 10th Revision [ICD-10] code C56) and cancer of the fallopian tubes and other uterine adnexa (ICD-10 C57) are leading causes of cancer mortality in women (ACS, 2016; CDC, 2016). Cancer of the...

  • Cancer
  • Epidemiology
  • Ovarian Cancer
  • Japan
  • Forecast
  • RISK FACTORS AND COMORBIDITIES FOR LUNG CANCER
  • MM, SOURCES USED FOR CANCER STAGE AT DIAGNOSIS

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently the most common cancer in the world, and is the most common cause of death from cancer worldwide. Of the total lung cancer incident cases, approximately 85% are the non-small cell lung cancer...

  • Cancer
  • Japan
  • Eli Lilly & Co.
  • Novartis AG
  • Pfizer Inc.
  • 13.Breast Cancer Screening Market Growth Drivers
  • 7.1 Korea Breast Cancer Mammography Screening Population &

Get 10% Free Customization in this Report Asia breast cancer screening market size is expected to cross over US$ 4 Billion by 2022. China, Japan and Korea are the top most contributors. Increasing breast cancer awareness, government and NGOs support breast cancer screening programs and ageing women population are major driving...

  • Cancer
  • East Asia
  • Japan
  • Forecast
  • Social Conditions
  • Lynparza's Development in Pancreatic Cancer
  • Masiviera's Development in Pancreatic Cancer

Pancreatic Cancer: Opportunity Analysis and Forecast to 2026 Summary Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer, despite accounting for only 3% of new cancer diagnoses. Patients with advanced pancreatic cancer have a median...

  • Cancer
  • Japan
  • AbbVie Inc.
  • AstraZeneca PLC
  • Halozyme Therapeutics, Inc.
  • MM, Sources Not Used in Epidemiological Analysis of Breast Cancer
  • 2.6.2 Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer

EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025 Summary Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that have grown beyond the ducts or lobules of the breast and can metastasize to other parts of the body through the bloodstream...

  • Breast Cancer
  • Cancer
  • Pathology
  • Japan
  • Forecast

Global Bladder Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • Japan
  • World

Global Esophageal Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Cancer
  • Esophageal Cancer
  • Pathology
  • Japan
  • World

Global Brain Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Brain Cancer
  • Cancer
  • France
  • Japan
  • Forecast

Global Breast Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Breast Cancer
  • Cancer
  • Pathology
  • Japan
  • World

Global Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • Japan
  • World

Global Prostate Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Cancer
  • Pathology
  • Prostate Cancer
  • Japan
  • World

Global Ovarian Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Cancer
  • Ovarian Cancer
  • Pathology
  • Japan
  • World

Global Gastric Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Cancer
  • Gastric Cancer
  • Pathology
  • Japan
  • World

Global Cervical Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Cancer
  • Cervical Cancer
  • Pathology
  • Japan
  • World

Global Colorectal Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Cancer
  • Colorectal Cancer
  • Pathology
  • Japan
  • World

Global Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Cancer
  • Lung Cancer
  • Pathology
  • Japan
  • World

Global Non-Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Cancer
  • Lung Cancer
  • Pathology
  • Japan
  • World
  • MM, Sources Used, Diagnosed Incident Cases of Oropharynx Cancer; Nasopharynx Cancer; Salivary Gland and
  • MM, DIAGNOSED INCIDENT CASES OF OROPHARYNX CANCER BY HISTOLOGY DISTRIBUTION AND BY RISK FACTOR (HPV), BOTH

Head and Neck Cancers: Epidemiology Forecast to 2026 Summary Head and neck cancers usually begin in the squamous cells that line the moist mucosal surfaces of the tissues and organs of the head and neck-more than 83% of all oral cavity and pharynx cancers are squamous cell carcinomas. They are the...

  • Cancer
  • Sexually Transmitted Disease
  • Japan
  • United States
  • Forecast
  • AJCC STAGING OF PROSTATE CANCER
  • Prostate Cancer: Executive Summary

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026 Summary Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.1 million men were diagnosed with prostate cancer in 2012 (IARC, 2017). In the...

  • Cancer
  • Pathology
  • Prostate Cancer
  • Japan
  • Forecast

Gastric cancer

4546 5000 3864
  • Marketed Drugs: Gastric Cancer
  • TREATMENT: GASTRIC CANCER

Pipeline therapies will look to fulfil many areas of high unmet need left by the lack of targeted therapies approved for the treatment of gastric cancer. This report addresses the following questions: - What impact will the PD-1/PD-L1 inhibitor class of drugs have on the gastric cancer market? - How will pipeline immunotherapies...

  • Cancer
  • Japan
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group
  • 4.1 BIBLIOGRAPHY
  • MM, Five-Year Diagnosed Prevalent Cases of SCLC Segmented by Stage at Diagnosis,

EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024 Summary Small Cell Lung Cancer (SCLC) is a distinct form of lung cancer that typically initially presents in the central airways before spreading to the submucosa, which leads to the narrowing of airways. SCLC is considered to be highly malignant due...

  • Cancer
  • Lung Cancer
  • Japan
  • Forecast
  • GlobalData's company
  • TREATMENT GUIDELINES FOR BLADDER CANCER
  • Opdivo's Development in Bladder Cancer

OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2025 Summary Bladder cancer is a urologic malignancy arising primarily from epithelial cells lining the bladder. In the vast majority of cases (>90%), bladder cancer manifests as transitional (urothelial) cell carcinoma (TCC). The remaining...

  • Bladder Cancer
  • Cancer
  • Japan
  • Merck & Co., Inc.
  • OncoGenex Pharmaceuticals, Inc.